PrimeRFP SCOUT · Federal Contract Recompete Brief

19AQMM22F41482022-2023 fluarix and flulaval vaccine delivery — Glaxosmithkline LLC

Glaxosmithkline LLC holds $3.0B across 194 federal awards, concentrated at Department of Health and Human Services (HHS). This PIID sits alongside 5 related awards under parent 36F79722D0178. The prior award was single-bid — competitive dynamics may favor a challenge. PoP ended Oct 6, 2022 — the usual 12–18 month planning window is closed; recompete action looks late or overdue.

Acquisitions - Aqm Momentum

Awarding office

Glaxosmithkline LLC

Recipient

Oct 6, 2022

PoP end

$634K

Obligated

$778K

Potential

325412

NAICS

6505

PSC

1 bidders on last award

Watch this recompete

One email. No account. We ping you if the window moves.

Score my position vs Glaxosmithkline LLC — $90

Contract facts

Federal

Contract number19AQMM22F4148

Also listed as19AQMM-22-F-4148

Also listed as36F79722D0178-19AQMM22F4148

AgencyAcquisitions - Aqm Momentum

Awarding officeAcquisitions - Aqm Momentum

Awarding agencyDepartment of State (DOS)

Funding agencyDepartment of State (DOS)

IncumbentGlaxosmithkline LLC

CAGE667E9

UEIFRHTPHMZMX47

NAICS325412

No full NAICS 325412 intel page yet. Browse NAICS intelligence

PSC6505

Parent IDIQ / IDV36F79722D0178

Place of performanceSTERLING VA

Pricing typeFirm Fixed Price

Extent competedFull And Open Competition

PoP startSep 23, 2022

PoP end (current)Oct 6, 2022

Obligated$634K

Current value$778K

Potential value$778K

2022-2023 FLUARIX AND FLULAVAL VACCINE DELIVERY ORDER. FOR DOS ACCOUNT. is a federal award for Acquisitions - Aqm Momentum held by Glaxosmithkline LLC. Estimated value $778K ($634K obligated). Current period of performance ends Oct 6, 2022. Last award drew 1 bidder. Place of performance: STERLING VA.

2022-2023 FLUARIX AND FLULAVAL VACCINE DELIVERY ORDER. FOR DOS ACCOUNT.

Recompete timing

Public

● Past PoP end (1415 days ago)

Current PoP ended Oct 6, 2022 (1415 days ago). The usual 12–18 month agency planning window is closed — recompete action looks late / overdue relative to a normal cycle. Watch for bridge orders, follow-ons, or a new solicitation.

Incumbent footprint

Public record

Glaxosmithkline LLC — $3.0B obligated across 194 awards (firm-wide, all agencies) · lead buyer Department of Health and Human Services (HHS).

% of firm-wide obligated ($3.0B) · all agencies

Department of Health and Human Services (HHS)$3.0B · 100%Department of Defense (DOD)$1.7M · 0%Department of Veterans Affairs (VA)$1.5M · 0%Department of State (DOS)$1.2M · 0%

Open full company profile →

Related awards

Same parent · incumbent

75A50125F61019

FILL/FINISH DOD AS03 ADJUVANT CLIN 1006E

$491K

Aug 30, 2026

75A50126F61020

TWO-WAY IMMUNOGENICITY TESTING ON EXISTING CLINICAL TRIAL SERA TO IMMUNOGENICITY SUPERIOR…

$493K

Oct 29, 2026

15F06724F0001366

GSK TRAVEL VACCINES

$115K

Dec 31, 2026

15F06726F0000234

GSK VACCINES TERMS AND CONDITIONS REMAIN THE SAME - BPA 15F06722A0000187

$105K

Dec 31, 2026

75A50124F61014

THIS TASK ORDER ESTABLISHES SERVICES FOR H5 PANDEMIC READINESS FOR ACQUISITION OF MEDICAL …

$18.4M

Feb 21, 2027

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →

Frequently asked questions

What is contract 19AQMM22F4148?

19AQMM22F4148 (2022-2023 fluarix and flulaval vaccine delivery) is a Acquisitions - Aqm Momentum award with a potential value of $778K, currently held by Glaxosmithkline LLC. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

What is 19AQMM-22-F-4148?

19AQMM-22-F-4148 is the dashed form of PIID 19AQMM22F4148 (2022-2023 fluarix and flulaval vaccine delivery), held by Glaxosmithkline LLC. Same award — SCOUT canonicalizes compact, dashed, and parent-child identifiers to one brief.

Which office awarded 19AQMM22F4148?

Acquisitions - Aqm Momentum awarded 19AQMM22F4148 to Glaxosmithkline LLC (potential $778K).

Who is the incumbent on 19AQMM22F4148?

Glaxosmithkline LLC is the incumbent with $3.0B across 194 related awards in SCOUT’s public footprint. The current period of performance ends Oct 6, 2022.

When does Glaxosmithkline LLC’s 19AQMM22F4148 come up for recompete?

SCOUT tracks a period-of-performance end of Oct 6, 2022. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of Aug 19, 2026 · refreshed monthlyLatest procurement action Jul 24, 2024